Tg Therapeutics, Inc.

This study tests the drug ublituximab in children aged 10 to 18 with relapsing multiple sclerosis (MS). It compares ublituximab to another drug, fingolimod, to see which better controls relapses. The trial involves 240 participants and will also monitor long-term safety and effec…

This study tests a drug called ublituximab, given as a shot under the skin, in 350 people with relapsing multiple sclerosis. Researchers want to see how the drug moves through the body when injected in different spots (like the belly or thigh) and whether an autoinjector pen work…

This study tracks 32 people who received Azer-Cel, an experimental cell therapy for B-cell related autoimmune diseases, to monitor long-term safety for up to 15 years. Participants are checked for serious side effects and disease changes. The goal is to understand risks over time…